All In Biotech

Drug Trial Radar · NCT05878860

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects With RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

97

Planned (sponsor's estimate)

Start

Aug 22, 2023

Primary completion

Apr 2028

Study completion Apr 2033

Sponsor

Lead sponsor
Atsena Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 5 years of age with RS1-associated X-linked retinoschisis (XLRS).

Conditions

  • X-linked Retinoschisis

Interventions

  • ATSN-201Biological

    AAV.SPR-hGRK1-hRS1syn

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Dose Escalation) and Part B (Dose Expansion): Safety and tolerability as assessed by dose-limiting toxicities and treatment-emergent adverse eventsTime frame: From baseline to week 52
  2. Part C (Phase 3, Randomized, Controlled) Effect of ATSN-201 on visual function.Time frame: From baseline to week 52

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona · Recruiting

  • Shiley Eye Institute

    La Jolla, California · Not yet recruiting

  • Children's Hospital of Los Angeles

    Los Angeles, California · Recruiting

  • Stanford University

    Palo Alto, California · Not yet recruiting

  • UC San Francisco

    San Francisco, California · Recruiting

  • Bascom Palmer Eye Institute

    Miami, Florida · Recruiting

  • Massachusetts Eye and Ear

    Boston, Massachusetts · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Not yet recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • Flaum Eye Institute, University of Rochester

    Rochester, New York · Not yet recruiting

  • Duke University

    Durham, North Carolina · Recruiting

  • Oregon Health Sciences University

    Portland, Oregon · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas · Recruiting

  • Moran Eye Center

    Salt Lake City, Utah · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Not yet recruiting

  • McGill University (MUHC)

    Montreal, Quebec, Canada · Not yet recruiting

  • Oxford Eye Hospital

    Oxford, England, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.